The U.S. Food and Drug Administration (FDA) has named Dr. George Tidmarsh as the new Director of the Center for Drug Evaluation and Research (CDER), signaling a notable shift in leadership for one of the agency’s most critical divisions. With over 30 years of experience in biotechnology, clinical development, and regulatory science, Dr. Tidmarsh brings a blend of academic knowledge and entrepreneurial expertise to the role.
Industry Veteran with a Track Record of Innovation
Dr. Tidmarsh is no stranger to the regulatory landscape. He has played a direct role in the successful development of seven FDA-approved drugs and has led several biopharmaceutical companies, including La Jolla Pharmaceutical and Threshold Pharmaceuticals. His experience spans oncology, critical care, and translational medicine, which aligns closely with CDER’s mission of ensuring the safety and efficacy of drugs entering the U.S. market (FDA, 2025).
In addition to his industry background, Dr. Tidmarsh has been a prominent figure in academia. He co-founded Stanford University’s Master of Translational Research and Applied Medicine (M-TRAM) program and has authored more than 140 peer-reviewed publications and patents. His dual focus on science and application gives him a well-rounded perspective on drug development challenges.
Leadership at a Pivotal Time
FDA Commissioner Dr. Marty Makary praised Tidmarsh’s appointment in an internal announcement, highlighting his ability to lead across government, academia, and private industry. The leadership change comes at a time when the FDA is managing increasing public and political scrutiny, drug approval backlogs, and calls for more transparent communication (Makary, 2025).
Tidmarsh replaces Acting Director Dr. Jacqueline Corrigan-Curay, who recently retired after nearly a decade of service. Her departure opened the door for a new direction, one that Makary believes will bring innovation and efficiency to CDER operations (RAPS, 2025).
Priorities and Early Signals
Shortly after his appointment, Dr. Tidmarsh appeared in an episode of FDA Direct, where he expressed his desire to enhance the agency’s review efficiency and consistency. He acknowledged the agency’s accomplishments but emphasized there is room for growth, particularly in streamlining decision-making processes (FDA, 2025).
Dr. Tidmarsh has also publicly voiced strong opinions on outdated and unapproved therapies. For instance, he has called for the removal of desiccated thyroid extract, labeling it as ineffective and harmful compared to modern synthetic alternatives. This stance suggests a potential focus on modernizing the FDA’s drug portfolio by eliminating legacy treatments that lack scientific backing (Tidmarsh, 2025).
Controversy and Transparency
Known for his outspoken views, Tidmarsh has not shied away from criticizing media coverage of FDA activities. He has publicly disputed how certain outlets interpret agency decisions, particularly around complete response letters (CRLs). His candidness has raised questions about how the agency may engage with the public and media moving forward.
His appointment also reflects a broader trend at the FDA to look outside its traditional ranks for leadership. Commissioner Makary noted that while internal candidates once filled the majority of top positions, recent years have seen a rise in external hires. This approach is designed to bring fresh perspectives into an organization that must continually adapt to a changing regulatory landscape (Makary, 2025).
Conclusion
Dr. George Tidmarsh’s appointment as CDER Director marks a significant leadership transition at the FDA. With a strong foundation in both science and business, and a clear vision for regulatory reform, Tidmarsh is poised to play a central role in shaping the future of drug evaluation in the United States.
At EMMA International, we help our clients stay ahead of regulatory changes and leadership transitions. Whether you are preparing a new drug application or monitoring agency updates, our team is here to guide you through every step of the process.
For more information on how EMMA International can assist, visit www.emmainternational.com. Contact EMMA International at (248) 987-4497 or by email at info@emmainternational.com to learn more.
